Allergies, Author Interviews, Dermatology, University of Michigan / 16.11.2023

MedicalResearch.com Interview with: Charles Schuler, MD Assistant Professor Allergy and Clinical Immunology & Mary H. Weiser Food Allergy Center University of Michigan MedicalResearch.com: What is the background for this study? Response: Anaphylaxis is a severe allergic reaction that may include a skin rash, nausea, vomiting, difficulty breathing, and shock. Food anaphylaxis sends 200,000 people to the emergency room annually in the United States. Oral food challenges are when a patient ingests increasing doses up to a full serving of the suspected food allergen under supervision of a medical provider, usually an allergist. These oral food challenges are the diagnostic standard for food allergy/anaphylaxis as skin and blood allergy tests have high false positive rates. Although a highly accurate test, patients often experience anaphylaxis during oral food challenges necessitating an epinephrine injection. (more…)
Annals Internal Medicine, Author Interviews, Dermatology / 14.11.2023

MedicalResearch.com Interview with: Ying Li MD, PhD Graduate School Chengdu University of Traditional Chinese Medicine Chengdu, China MedicalResearch.com: What is the background for this study? Response: Chronic spontaneous urticaria (CSU) is a prevalent dermatological condition affecting approximately 1% of the global population. It is characterized by persistent itching and the development of hives, significantly impairing patients' quality of life. More than 90% of patients with CSU require urgent medical treatment to relieve itching. However, few therapies are specifically designed to treat pruritus in The management of pruritus is one of the main goals in the treatment of chronic spontaneous urticaria . Antihistamines are a common treatment of CSU, and current guidelines recommend second-generation antihistamines as first-line therapy. However, nearly 40% of patients do not respond to second-generation antihistamines, even when the dose is increased 2- to 4-fold. Omalizumab as a second-line treatment is effective in controlling urticaria, but it is costly and is not reimbursed in many countries, limiting its use to most patients worldwide. Given the shortcomings of existing therapies for pruritus in CSU, novel therapeutic interventions or strategies are emerging. Acupuncture, a traditional physical therapy with a rich historical background spanning over a millennium, has been regarded as an effective treatment for urticaria in China. However, previous randomized controlled trials investigating acupuncture's efficacy have been marred by methodological limitations, thereby undermining the credibility of the evidence. To address this gap, we conducted a multicenter randomized controlled trial to comprehensively evaluate the effectiveness of acupuncture in the management of CSU. (more…)
Author Interviews, Dermatology, JAMA, NYU / 19.12.2018

MedicalResearch.com Interview with: Nicholas A. Soter, MD The Ronald O. Perelman Department of Dermatology New York University School of Medicine New York, New York MedicalResearch.com: What is the background for this study? Response: Nearly 50% of patients with chronic spontaneous urticarial (CSU) (hives) incompletely respond to first-line therapy with H-1 antihistamines. However, in the current literature, there is limited evidence to guide the treatment of CSU after maximal therapy with antihistamines fails.  Two small, randomized, controlled trials suggest that dapsone, which is an antimicrobial therapeutic agent with anti-inflammatory properties, may be a useful second-line therapeutic agent. (more…)
Allergies, Author Interviews, Dermatology, Immunotherapy, JAMA / 17.11.2018

MedicalResearch.com Interview with: Christopher S. Lee, PhD, RN, FAHA, FAAN, FHFSA Professor and Associate Dean for Research Boston College William F. Connell School of Nursing Chestnut Hill, MA 02467 MedicalResearch.com: What is the background for this study? Response: Although the efficacy of omalizumab (i.e. can it work?) in the treatment of chronic idiopathic (spontaneous) urticaria has been established in clinical trials, the effectiveness of omalziumab (i.e. does it work?) in the real-world management is less well established. The purpose of this study was to synthesize what is known about the benefits and harms of omalizumab as used in real-world treatment of Chronic Idiopathic (Spontaneous) Urticaria. (more…)
Allergies, Author Interviews, Dermatology, JAMA, Pediatrics / 28.09.2017

MedicalResearch.com Interview with: Elena Netchiporouk, MD, FRCPC, MSc Dermatology Resident - PGY5 and Dr. Moshe Ben-Shoshan, MD, FRCPC, MSc McGill University MedicalResearch.com: What is the background for this study? Response: We have followed a pediatric cohort of 139 patients with chronic urticaria (CU) (hives) between 2013 and 2015 in a single tertiary care center and assessed the comorbidities, the rate of resolution and determined predictors of resolution. (more…)